The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Eli Lilly and ...

Eli Lilly’s crop of new products propelled ... s chief financial officer Josh Smiley on the company’s results call, adding that Trulicity “grew faster than the market, hosting an increase ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...

Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device ...